# Furosemide

## Lasix inj 20mg/2mL

| 藥物代碼 | ILAS |
| :--- | :--- |
| 適應症 | Cardiac, renal & hepatic edema; edema due to burns; mild to moderate hypertension, Acute pulmonary edema, Forced diuresis. |
| 副作用 | Minor GI upset; Ca, K & Na depletion, nephrocalcinosis in premature infants; aggravation of metabolic alkalosis; diabetes. Rarely, anaphylactic shock, allergic reactions, bone marrow depression; acute pancreatitis, auditory disorders.Endocrine metabolic: Hyperuricemia \(40%\), HypomagnesemiaGastrointestinal: Loss of appetiteRenal: Spasm of bladder |
| 禁忌 | Acute renal failure with anuria, hepatic coma, hypokalemia, hyponatremia, hypovolemia with or without hypotension. Impaired renal or hepatic function. |
| 藥物保存方式 | N/A |
| 用法用量 | Adult & children &gt;15 years Initially 20-40 mg IM or IV, may increase stepwise by 20 mg at 2-hr interval. Acute pulmonary edema Initially 40 mg IV, then 20-40 mg after 20 mins. Forced diuresis 20-40 mg with electrolyte soln infusion. Infant & children &lt;15 years 1 mg/kg body weight IM or IV up to 20 mg daily. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | Human data suggest low risk |
| 附帶說明 | \[仿單\] Furosemide 會通過胎盤障壁，因此，除非有強制性的醫學理由， 否則不可於懷孕期間使用 Lasix。 若於懷孕期間使用Lasix，則須監測胎兒的發育情形。 |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Probably Compatible 無\(很少\)資料 - 可使用 |
| 附帶說明 | \[仿單\] Furosemide 會移行進入乳汁中，並抑制乳汁分泌，因此，不可於餵哺母乳期間使用 Lasix。 |
| 注射劑給藥建議途徑 | IM, IVD, IVP, IVPUSH |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | 【D5W】 可選 仿單建議  【L/R】 可選 仿單建議  【N/S】 可選 仿單建議 |
| IVP 用法建議 | 推注時間至少 5分鐘 |
| IVD 用法建議 | 滴注速率 &lt;4mg/min,稀釋後pH值須維持在弱鹼 \(7-10之間\) |
| 注意事項 | 1.pH&gt;5.5時IVD &lt; 4mg/min 2.未稀釋亦可使用 3.避光使用，溶液變色即不可使用 |

## Fumide solution 10mg/mL 120mL

| 藥物代碼 | LFUM |
| :--- | :--- |
| 適應症 | Edema: Management of edema associated with heart failure and hepatic or renal disease; acute pulmonary edema.Hypertension: Management of hypertension.Note: Not recommended for the initial treatment of hypertension. |
| 副作用 | Cardiovascular: Necrotizing angiitis, orthostatic hypotension, thrombophlebitis, vasculitisCentral nervous system: Dizziness, headache, paresthesia, restlessness, vertigoDermatologic: Acute generalized exanthematous pustulosis, bullous pemphigoid, erythema multiforme, exfoliative dermatitis, pruritus, skin photosensitivity, skin rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticariaEndocrine & metabolic: Glycosuria, hyperglycemia, hyperuricemia, increased serum cholesterol, increased serum triglyceridesGastrointestinal: Abdominal cramps, anorexia, constipation, diarrhea, gastric irritation, mouth irritation, nausea, pancreatitis, vomitingGenitourinary: Bladder spasmHematologic & oncologic: Agranulocytosis, anemia, aplastic anemia, eosinophilia, hemolytic anemia, leukopenia, purpura, thrombocytopeniaHepatic: Hepatic encephalopathy, intrahepatic cholestatic jaundice, liver enzymes increasedHypersensitivity: Anaphylaxis, anaphylactoid reaction, anaphylactic shockImmunologic: DRESS syndromeLocal: Pain at injection site \(following IM injection\)Neuromuscular & skeletal: Muscle spasm, weaknessOphthalmic: Blurred vision, xanthopsiaOtic: Deafness, tinnitusRenal: Interstitial nephritis \(allergic\), renal diseaseMiscellaneous: Fever |
| 禁忌 | Hypersensitivity to furosemide or any component of the formulation.hepatic cirrhosis; renal failure accompanied by hepatic coma and precoma; renal failure due to poisoning with nephrotoxic or hepatotoxic substances. |
| 藥物保存方式 | 室溫 |
| 用法用量 | Edema: Adult: Oral: Initial: 20 to 80 mg/dose; if response is not adequate, may repeat the same dose or increase dose in increments of 20 to 40 mg/dose; may titrate up to 600 mg/day with severe edematous states; usual maintenance dose interval is once or twice daily. Heart failure: Initial: 20 to 40 mg once or twice daily; maximum 600 mg/day. Edema: Infants, Children, and Adolescents: Oral: Initial: 2 mg/kg/dose increased in increments of 1 to 2 mg/kg/dose with each succeeding dose at intervals of 6 to 8 hours until a satisfactory response is achieved; maximum dose: 6 mg/kg/dose. Hypertension, resistant \(off-label use\): Children and Adolescents 1 to 17 years: Oral: Initial: 0.5 to 2 mg/kg/dose once or twice daily; maximum dose: 6 mg/kg/dose. |
| 肝功能異常 | 需 調 整 劑 量  Diminished natriuretic effect with increased sensitivity to hypokalemia and volume depletion in cirrhosis. Monitor effects, particularly with high doses. |
| 腎功能異常 | 需 調 整 劑 量 |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | Human data suggest low risk |
| 附帶說明 | UpToDate: Pregnancy Risk Factor: C \(above table\) |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Probably Compatible 無\(很少\)資料 - 可使用 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | AC, PC, PO |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

## Lasix 40mg

| 藥物代碼 | OLAS |
| :--- | :--- |
| 適應症 | Cardiac, renal & hepatic edema; edema due to burns; mild to moderate hypertension |
| 副作用 | Minor GI upset; Ca, K & Na depletion, nephrocalcinosis in premature infants; aggravation of metabolic alkalosis; diabetes. Rarely, anaphylactic shock, allergic reactions, bone marrow depression; acute pancreatitis, auditory disorders.Endocrine metabolic: Hyperuricemia \(40%\), HypomagnesemiaGastrointestinal: Loss of appetiteRenal: Spasm of bladder |
| 禁忌 | Acute renal failure with anuria, hepatic coma, hypokalemia, hyponatremia, hypovolemia with or without hypotension. Impaired renal or hepatic function. |
| 藥物保存方式 | 室溫 |
| 用法用量 | Cardiac, renal & hepatic edema; edema due to burns; mild to moderate hypertension Tab/Oral soln Adult Initially 40 mg daily; maintenance 20-40 mg daily, increased in resistant oedema to 80 mg daily or more. Children 1-3 mg/kg daily. Max: 40 mg daily. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | Human data suggest low risk |
| 附帶說明 | \[仿單\] Furosemide 會通過胎盤障壁，因此，除非有強制性的醫學理由， 否則不可於懷孕期間使用 Lasix。 若於懷孕期間使用Lasix，則須監測胎兒的發育情形。 |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Probably Compatible 無\(很少\)資料 - 可使用 |
| 附帶說明 | \[仿單\] Furosemide 會移行進入乳汁中，並抑制乳汁分泌，因此，不可於餵哺母乳期間使用 Lasix。 |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

